Match!
Laura Mauri
Harvard University
CardiologyStentPercutaneous coronary interventionMyocardial infarctionMedicine
434Publications
68H-index
29.1kCitations
What is this?
Publications 440
Newest
#1Erika Di Biase (University of Milan)H-Index: 1
#2Giulia Lunghi (University of Milan)H-Index: 1
Last. Simona Prioni (University of Milan)H-Index: 19
view all 13 authors...
It has been recently reported by our group that GM1-oligosaccharide added to neuroblastoma cells or administered to mouse experimental model mimics the neurotrophic and neuroprotective properties of GM1 ganglioside. In addition to this, differently from GM1, GM1-oligosaccharide is not taken up by the cells, remaining solubilized into the extracellular environment interacting with cell surface proteins. Those characteristics make GM1-oligosaccharide a good tool to study the properties of the endo...
Source
Source
Many species of ganglioside GM1, differing for the sialic acid and ceramide content, havebeen characterized and their physico‐chemical properties have been studied in detail since 1963.Scientists were immediately attracted to the GM1 molecule and have carried on an ever‐increasingnumber of studies to understand its binding properties and its neurotrophic and neuroprotectiverole. GM1 displays a well balanced amphiphilic behavior that allows to establish strong bothhydrophobic and hydrophilic inte...
Source
#1Sara GrassiH-Index: 6
#2Paola GiussaniH-Index: 19
Last. Alessandro PrinettiH-Index: 36
view all 6 authors...
Source
#1Elena Chiricozzi (University of Milan)H-Index: 6
#2Laura Mauri (University of Milan)H-Index: 68
Last. Sandro Sonnino (University of Milan)H-Index: 54
view all 19 authors...
Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1+/− mice, a model of sporadic Parkinson’s disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransm...
2 CitationsSource
#1Natalia C. Berry (Brigham and Women's Hospital)H-Index: 2
#2Laura Mauri (Brigham and Women's Hospital)H-Index: 68
Last. Sanjiv J. Shah (NU: Northwestern University)H-Index: 51
view all 8 authors...
Background A randomized, sham-controlled trial in patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≥40% demonstrated reductions in pulmonary capillary wedge pressure (PCWP) with a novel transcatheter InterAtrial Shunt Device (IASD). Whether this hemodynamic effect will translate to an improvement in cardiovascular outcomes and symptoms requires additional study. Study Design and Objectives REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUC...
Source
#1Saibal Kar (Cedars-Sinai Medical Center)H-Index: 42
#2Ted Feldman (NorthShore University HealthSystem)H-Index: 71
Last. Patrick L. Whitlow (Cleveland Clinic)H-Index: 59
view all 17 authors...
Objectives This study evaluates the 5-year clinical outcomes of transcatheter mitral valve (MV) repair with the MitraClip device in patients at high risk for MV surgery treated in the Endovascular Valve Edge-to-Edge Repair (EVEREST) II High Risk Study (HRS). Methods Patients with mitral regurgitation (MR) 3+ or 4+ and predicted surgical mortality risk ≥12% or surgeon assessment based on prespecified high-risk factors were enrolled. Patients prospectively consented to 5 years of follow-up. Result...
7 CitationsSource
#1Hector M. Garcia-Garcia (MedStar Washington Hospital Center)H-Index: 67
#2Eugene P. McFadden (Cork University Hospital)H-Index: 63
Last. Pascal Vranckx (University of Hasselt)H-Index: 40
view all 18 authors...
Abstract Objectives This study sought to explore the association between biomarker elevation, with creatine kinase–myocardial band (CK-MB) or cardiac troponin (cTn), following percutaneous coronary intervention (PCI) and mortality in patients undergoing PCI for stable angina with normal baseline values. Background Several studies have shown a strong association between post-PCI CK-MB elevation and subsequent mortality. However, the prognostic significance of troponin elevation following coronary...
4 CitationsSource
#1Shamir R. Mehta (UBC: University of British Columbia)H-Index: 1
#2David A. Wood (UBC: University of British Columbia)H-Index: 43
Last. John Cairns (UBC: University of British Columbia)H-Index: 59
view all 32 authors...
Abstract Background In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or m...
29 CitationsSource
#1Ada Stefanescu (Harvard University)H-Index: 7
#2Gabriel Steg (Imperial College London)H-Index: 119
Last. Dapt Study InvestigatorsH-Index: 1
view all 10 authors...
Abstract The risk of major adverse cardiac and cerebrovascular events (MACCE) in subjects who interrupt temporarily or permanently thienopyridine therapy in the first 6 months after percutaneous coronary intervention (PCI) remains uncertain. In the Dual Antiplatelet Therapy (DAPT) Study subjects were enrolled within 72 hours of PCI and treated with aspirin and a thienopyridine for 12 months before being randomized to continued thienopyridine vs. placebo. This analysis focuses on the 12-month per...
Source
12345678910